Comparison of CYP2B6 *6 and *1/*1 patients for baseline features
| . | *1/*1 patients (n = 265) . | *1/*6 & *6/*6 patients (n = 163) . | P value . |
|---|---|---|---|
| Age median, y (range) | 64 (42-83) | 65 (42-85) | .712 |
| Sex (M:F) | 2.8:1 | 2.5:1 | .683 |
| Stage A | 67 (25%) | 35 (21%) | .658 |
| Stage B | 121 (46%) | 77 (47%) | |
| Stage C | 77 (29%) | 51 (31%) | |
| TP53 mutation or deletion | 19/242 (8%) | 11/151 (7%) | .837 |
| 11q– | 48/242 (20%) | 31/154 (20%) | .943 |
| +12 | 24/242 (10%) | 20/154 (13%) | .343 |
| 13q– | 97/242 (40%) | 64/154 (42%) | .771 |
| Unmutated IGHV | 134/225 (60%) | 83/138 (60%) | .912 |
| . | *1/*1 patients (n = 265) . | *1/*6 & *6/*6 patients (n = 163) . | P value . |
|---|---|---|---|
| Age median, y (range) | 64 (42-83) | 65 (42-85) | .712 |
| Sex (M:F) | 2.8:1 | 2.5:1 | .683 |
| Stage A | 67 (25%) | 35 (21%) | .658 |
| Stage B | 121 (46%) | 77 (47%) | |
| Stage C | 77 (29%) | 51 (31%) | |
| TP53 mutation or deletion | 19/242 (8%) | 11/151 (7%) | .837 |
| 11q– | 48/242 (20%) | 31/154 (20%) | .943 |
| +12 | 24/242 (10%) | 20/154 (13%) | .343 |
| 13q– | 97/242 (40%) | 64/154 (42%) | .771 |
| Unmutated IGHV | 134/225 (60%) | 83/138 (60%) | .912 |